Press Release

01 Nov Braeburn Announces FDA Advisory Committee Recommends Approval of CAM2038 Buprenorphine Depot for the Treatment of Opioid Use Disorder

Posted at 15:56h in Press Release

Recommendation based on review of clinical data comprising a broad, real-world opioid use disorder (OUD) population including patients who had...

05 Oct Braeburn CEO Participates in U.S. Department of Health and Human Services Secretarial Round Table Discussion on Opioids

Posted at 15:52h in Press Release

Princeton, N.J.—October 5, 2017 — Braeburn Pharmaceuticals, Inc. (Braeburn) today participated in a roundtable discussion at the U.S Department of...

27 Sep Braeburn Participates in President’s Commission Meeting on Combating Drug Addiction and the Opioid Crisis

Posted at 15:48h in Press Release

Princeton, N.J. — September 27, 2017 — Braeburn Pharmaceuticals, Inc. (Braeburn) today participated in the Third Meeting of the President’s...

18 Sep FDA Acceptance of NDA for CAM2038 for Opioid Use Disorder

Posted at 15:38h in Press Release

Braeburn Announces FDA Acceptance with Priority Review of New Drug Application for CAM2038 Buprenorphine Depot for the Treatment of Opioid...

20 Jul Braeburn and Camurus Announce Submission for CAM2038 for Opioid Use Disorder

Posted at 15:29h in Press Release

Braeburn and Camurus Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder If approved, CAM2038 would provide...

12 Jul Topline Phase 2 Results for Long-acting Buprenorphine in Opioid Dependent Patients with Chronic Pain

Posted at 15:22h in Press Release

Camurus and Braeburn Pharmaceuticals Announce Topline Phase 2 Results for Long-acting Buprenorphine in Opioid Dependent Patients with Chronic Pain Lund, Sweden...

22 Jun Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms

Posted at 15:04h in Press Release

Phase 2 Trial Demonstrates Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder New data...

13 Jun Braeburn and Knight Therapeutics Announce Filing of PROBUPHINE® in Canada

Posted at 19:39h in Press Release

Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE® in Canada for Opioid Drug Dependence PRINCETON, N.J....

05 Jun Braeburn Pharmaceuticals Names Mike Derkacz as President and CEO

Posted at 17:02h in Press Release

Braeburn Pharmaceuticals Names Mike Derkacz as President and CEO, former Head of CNS and Pain Therapeutics for Teva Pharmaceuticals Braeburn President...

02 May Braeburn and Camurus Announce Positive Top-line Results from CAM2038 Safety Study

Posted at 19:39h in Press Release

Princeton, New Jersey and Lund, Sweden — 2 May 2017 — Braeburn Pharmaceuticals and Camurus (NASDAQ STO: CAMX) today announced...

Define the future at Braeburn...together.

Join Our Team